null Allan Sniderman, MD
prevention • cardiovascular • disease • atherosclerosis • apoB • apoA-1
The objective of my research is to simultaneously simplify and improve the diagnosis and treatment of the atherogenic dyslipoproteinemias with the use of apoB; to improve the effectiveness of primary prevention of cardiovascular disease by the application of the Benefit model; and to determine if injury to the pancreas due to excess uptake of LDL particles contributes to the pathogenesis of type 2 diabetes mellitus.
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA.JAMA Cardiol. 2019 Dec 1;4(12):1287-1295.
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, Wilkins JT, Thanassoulis G.J Lipid Res. 2018 Jul;59(7):1266-1275.
The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Pencina MJ, Pencina KM, Lloyd-Jones D, Catapano AL, Thanassoulis G, Sniderman AD. Circulation. 2020 Sep;142(9):827-837.
Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB Sr, Peterson ED, Sniderman AD. Circulation. 2019 Mar 26;139(13):1603-1611.